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The cause of renal fibrosis in diabetic nephropathy is widely
believed to be phenotypic switching of fibroblasts to an
activated state. However, emerging evidence suggests that
diabetes also alters the phenotype of normal, non-fibroblast
kidney cells, such as mesangial cells, tubular epithelial cells,
and bone marrow-derived progenitors. Experiments have
shown that cytokines, high glucose, and advanced glycation
end products induce profibrotic changes in kidney cell
phenotype by the processes of myofibroblast
transdifferentiation and epithelial–mesenchymal transition.
As a result, differentiated kidney cells become reprogrammed
to secrete and accumulate extracellular matrix. This revised
view implies that inhibiting phenotypic transitions in
nonfibroblasts might limit fibrosis in diabetic nephropathy.
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In susceptible individuals, diabetes can cause progressive
renal fibrosis, eventually reducing functioning renal mass.
Fibrosis arises, in part, through ‘activation’ of renal
fibroblasts to secrete and remodel the extracellular matrix.
In nondiabetic kidney disease, studies strongly suggest that
matrix-producing effector cells also arise from phenotypic
transitions in mesangial cells and tubular epithelial cells.
Profibrotic switches in the phenotype of mesangial and
epithelial cells might also promote fibrosis in diabetic
nephropathy.
Phenotypic changes of two types have been observed in
experimental and clinical studies of diabetic nephropathy:
myofibroblast transdifferentiation (MFT) and epithelial–
mesenchymal transition (EMT). Yet, surprisingly little research
has focused on MFT and EMT in progressive renal fibrosis in
diabetes. The following review proposes a role for MFT and
EMT in the pathogenesis of fibrosis in diabetic nephropathy
and identifies crucial questions for future research.
PHENOTYPE SWITCHING AND FIBROSIS IN CHRONIC
KIDNEY DISEASE
In patients with diabetic nephropathy, fibrosis develops in the
glomerulus and tubulointerstitium (see Ziyadeh and Sharma1;
Mason and Abdel Wahab2; Caramori and Mauer3; Wolf
et al.4; Fogo and Kashgarian5; Eddy6 for review), consistent
with the development of fibrosis in most chronic kidney
disease. Although renal fibrosis in diabetes is generally viewed
as irreversible, some studies suggest that remission or
regression is possible6–11. In diabetes, extracellular matrix
accumulates in the glomerular mesangium, and in large
cross-sectional studies, the increment in mesangial matrix
correlates inversely with capillary filtration surface area and
glomerular filtration rate.3 Glomerular fibrosis occurs early in
the progression from incipient to overt nephropathy.2,3 In
some patients, tubulointerstitial fibrosis also appears early in
diabetic kidney injury, but it is more prominent later in the
disease and closely correlates with the decline in renal
function.3,12–15 In patients with advanced fibrotic lesions,
transglutaminases crosslink proteins, forming a matrix
resistant to degradation by metalloproteinases. Profibrotic
mediators, including transforming growth factor b (TGFb),
connective tissue growth factor, angiotensin II, endothelin-1,
and fibroblast growth factor have been identified,1,2,16–18
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most of which are also elevated in diabetic nephropathy.2
Whether or not renal fibrosis is reversible, inhibition of these
profibrotic mechanisms remains a promising therapeutic
target in the diabetic kidney.9,18
A crucial advance in our understanding of renal fibrosis in
nondiabetic kidney disease is that multiple cell types are
responsible for accumulation and remodeling of extracellular
matrix.19–21 Although fibroblasts are critical effectors of renal
fibrosis, changes in the phenotype of intrinsic, nonfibroblas-
tic kidney cells play an important role (Figure 1). MFT and
EMT result from reprogramming of cells by cytokines and
growth factors, and MFT and EMT have been widely
characterized in normal embryonic development and in
diverse pathological processes.20–28 In tissue injury, MFT and
EMT produce effector cells that secrete matrix proteins,
especially the fibrillar collagens and fibronectin, which serve
as scaffolds for assembly and remodeling of the extracellular
matrix into a fibrotic lesion.29,30 Cells undergoing MFT and
EMT also secrete protease inhibitors, cytokines, growth
factors, and inflammatory mediators that amplify the fibrotic
process by recruiting neighboring cells in a paracrine manner
(Figure 2). As discussed below, effector cells in renal fibrosis
can also arise from bone marrow-derived progenitors.
Important questions to consider are: does MFT and EMT
occur in diabetic nephropathy? If so, does MFT and EMT
contribute to renal fibrosis?
PHENOTYPIC TRANSITIONS IN FIBROSIS: NOMENCLATURE
Before continuing, it is necessary to consider the definitions
of MFT and EMT to avoid confusion. In this review, MFT and
EMT are defined as processes that fundamentally alter the
structure and function of mesenchymal, epithelial, or
progenitor cells depending on whether the target cell is
mesenchymal or epithelial. MFT and EMT are considered by
some investigators to belong to the general class of
phenotypic transitions known as metaplasias.31–34 Changes
in cell growth sometimes accompany MFT and EMT, but this
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Figure 1 | MFT and EMT produce effector cells in renal fibrosis.
(a) MFT alters the normal phenotype of glomerular mesangial cells to
produce myofibroblasts that secrete excess extracellular matrix.
Prolonged transdifferentiation of mesangial cells can lead to fibrosis.
Fibroblasts or microvascular pericytes in the tubulointerstitium might
also undergo MFT. It is unclear whether mesangial or fibroblast MFT
is reversible. (b) EMT is another phenotypic transition that produces
profibrotic effector cells. Tubular epithelial cells respond to stress
signals by undergoing EMT and producing fibroblastic cells that
migrate across the tubular basement membrane into the interstitium.
In chronic kidney disease, effector cells deriving from EMT are
postulated to cause tubulointerstitial fibrosis, which is closely
associated with progression to end-stage kidney disease.
(c) Examples of the phenotypic changes that result from MFT and
EMT. Although MFT and EMT have been well studied in nondiabetic
kidney disease, their role in diabetic nephropathy is being
investigated.
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Figure 2 | In diabetic nephropathy, diverse cell types undergo
MFT and EMT to produce profibrotic effectors. At least four
distinct cell types undergo metaplastic changes in the diabetic
kidney: (from left to right) mesangial cells, bone marrow-derived
progenitors, interstitial fibroblasts, and tubular epithelial cells. Both
MFT and EMT contribute to tubulointerstitial fibrosis. It is unclear
whether microvascular pericytes of the peritubular capillaries can also
be targeted by MFT. MFT results in myofibroblasts that contribute to
fibrosis in the glomerulus and tubulointerstitium. In contrast, EMT of
tubular epithelial cells produces fibroblastic cells that migrate into
the interstitial space. In practice, the lack of stage-specific markers
precludes a precise distinction between the phenotypes of
myofibroblasts and fibroblastic cells that derive from the epithelium.
There might, in fact, be significant overlap.
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is not always the case.33 In nature, metazoan development
depends on MFT- and EMT-like changes in progenitor or
stem cells, and on the reverse process of EMT the
mesenchymal epithelial transition.35 In adult cells with fixed
physiological functions, MFT and EMT can have deleterious
effects and often play a critical role in pathophysiology that
involves altered cell growth or dysplasia.
Phenotypic changes in the form of MFT drive glomerulo-
sclerosis by altering the phenotype of mesangial cells and
possibly bone marrow-derived progenitors (Figure 1). MFT
of fibroblasts, and perhaps also extraglomerular vascular
pericytes, contributes to tubulointerstitial fibrosis. Mesangial
cells are microvascular pericytes that provide structural
support for glomerular capillaries and resist the high
hydraulic pressure required to achieve ultrafiltration.36–38 In
patients with diabetes, mesangial cell hypertrophy, expanded
mesangial matrix, thickening of the glomerular basement
membrane, and obliteration of glomerular capillaries char-
acterizes glomerulosclerosis. In response to injury, mesangial
cells can transdifferentiate into myofibroblasts, a specialized
population of mesenchymal cells that secrete extracellular
matrix, particularly the fibril-forming collagens and fibro-
nectin (Figure 2). Production of interstitial collagens by
myofibroblasts contrasts with the lack of collagen I synthesis
by mesangial cells in the normal, nondiabetic kidney.2,39
Mesangial MFT, sometimes called ‘activation’, is postulated to
participate in endothelial and podocyte injury and in
secondary tubulointerstitial injury. MFT also precedes
expansion of the mesangial matrix and glomerulosclero-
sis,2,40,41 consistent with a pathogenic role. Whether the same
mechanisms regulate MFT in mesangial cells and phenotypic
activation of fibroblasts is unknown.
In contrast to MFT, tubular epithelial cells undergo a
unique phenotypic change known as EMT (Figure 1), which
drives tubulointerstitial fibrosis in response to growth factors
and profibrotic cytokines such as TGFb.20,21,26,27,42 EMT of
tubular epithelium challenges our long-held view that these
cells are terminally differentiated and reflects the remarkable
phenotypic plasticity of epithelial cells.
A function for EMT in the etiology of renal fibrosis was
first suggested in rodent models of anti-tubular basement
membrane disease43 and reduced renal mass by 5/6
nephrectomy.44 EMT has also been reported in obstructive
nephropathy, anti-glomerular basement membrane disease,
and nephrotoxic serum nephritis.27 A hallmark of EMT is the
loss of E-cadherin at adherens junctions, distortion of
epithelial cell polarity, and disorganization of cell–cell
adhesion junctions.45 This loss of epithelial barrier function
results in effector cells that migrate into the interstitial
extracellular matrix (Figure 2). Tubular cells that undergo
EMT also secrete matrix proteins and inflammatory media-
tors. EMT of tubular epithelium and MFT of intertubular
pericytes might be especially important because clinical
studies have associated epithelial injury and tubulointerstitial
fibrosis with increased risk of progression in diabetic
nephropathy.12,13
IDENTIFYING PHENOTYPIC TRANSITIONS IN DIABETIC
NEPHROPATHY: MARKERS OF MFT AND EMT
MFT and EMT alter expression of cytoskeletal proteins and
reorganization of actin filaments, making it possible to use
morphological and immunohistochemical markers to identi-
fy cells that have undergone MFT or EMT. For example,
myofibroblasts have an elongated, spindle-shaped morphol-
ogy with extended cell processes.46 a-Smooth muscle actin
(aSMA) – absent in normal mesangial, tubular epithelial, and
fibroblastic cells – is prominent in myofibroblasts and is the
most common marker used to localize MFT and EMT in vivo.
Upregulation of aSMA facilitates myofibroblast contraction
in wound healing and fibrosis. aSMA also functions as a
mechanotransducer that responds to signals received at focal
adhesions. Fibroblast-specific protein 1 (also known as
S100A4 and MTS1) is another marker which has been used
in clinical and experimental studies. It specifically localizes to
fibroblasts,27,43 but probably does not differentiate between
‘activated’ and resting fibroblasts. Glomerular mesangial cells
do not express fibroblast-specific protein 143 Not surpris-
ingly, upregulation of procollagen Ia2 marks activated
fibroblasts and myofibroblasts and is also a useful marker
to identify cells which have undergone MFT and EMT.
However, a drawback to using procollagen Ia2 is that
expression can be demonstrated in other cell types as well.47
Although these markers have been used successfully to
identify metaplastic cells, the lack of specific myofibroblast
markers hinders studies of MFT and EMT, particularly in
animal models. At present there are no genetic markers of
MFT or EMT. The development of selective, ‘stage-specific’
MFT and EMT markers is important, and noninvasive
biomarkers are needed for clinical studies involving MFT
and EMT.
PHENOTYPIC TRANSITIONS IN EXPERIMENTAL MODELS
OF DIABETIC NEPHROPATHY
Analysis of MFT and EMT in diabetic animals demonstrates
that prominent changes in renal cell phenotype occur in
diabetes. For example, kidneys from the KKay mouse model
of diabetic nephropathy have been shown to express MFT
markers,48 and in the obese Zucker fa/fa diabetic rat, MFT
was observed in the tubulointerstitium but not in glomer-
uli.49 In the Zucker rat, matrix deposition correlated with
MFT of tubulointerstitial fibroblasts, implicating MFT in the
development of tubulointerstitial fibrosis.49 MFT has also
been reported in glomeruli from rats made diabetic with
streptozotocin (STZ).50,51 In addition, STZ mice displayed
evidence of MFT in tubulointerstitial fibroblasts. Typically,
glomerular MFT markers temporally and spatially associate
with accumulation of collagen type I, IV, and with a
transcriptional effector of TGFb signaling, SMAD1.50,51
In addition to MFT, several studies suggest that EMT of
tubular epithelial cells occurs in diabetes. EMT markers in the
kidney have been reported in Wistar Kyoto and Sprague–-
Dawley normotensive rats treated with STZ,42,52 and EMT
was attenuated by a crosslink breaker that neutralized the
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effect of advanced glycation end products (AGEs) in vivo,
which suggests a role for AGEs.52 Consistent with this notion,
the receptor for AGEs has been shown to induce EMT by a
TGFb-dependent pathway in cultured tubule epithelium.52
Taken together, these results demonstrate that MFT and EMT
occur in the diabetic kidney and that they can be studied
experimentally in rodent models. Future studies of MFT and
EMT in diabetes should reveal mechanisms of regulation and
the functional role in renal fibrosis.
DO MFT AND EMT OCCUR IN PATIENTS WITH DIABETIC
NEPHROPATHY?
Markers of MFT and EMT have been observed in the kidneys
of patients with diabetic nephropathy. For instance, renal
biopsies from healthy subjects did not reveal any aSMA-
positive myofibroblasts,53,54 demonstrating that MFT is rare
in normal kidney. In contrast, biopsies performed on diabetic
patients documented the presence of MFT markers in the
tubulointerstitium52–55 and in glomeruli associated with
mesangial matrix expansion.52,53,56
EMT has also been identified in biopsies of patients with
diabetic nephropathy55 and strong correlations were observed
between EMT and fractional area of the interstitium (an
index of tubulointerstitial fibrosis) and collagen type III.53,54
In fact, EMT, MFT, proteinuria, and the decline in renal
function are tightly correlated, leading two groups to
recommend aSMA immunostaining as a biomarker for renal
fibrosis in patients with diabetes.53,54 Taken together, these
findings suggest that normal cells in the diabetic kidney are
undergoing MFT and EMT, contrasting earlier theories that
the cause of renal fibrosis is only because of phenotypic
switching of fibroblasts.
PHENOTYPIC TRANSITIONS OF BONE MARROW-DERIVED
PROGENITOR CELLS: A NOVEL PATHWAY TO RENAL FIBROSIS
Although the experimental and clinical studies discussed
above suggest that MFT and EMT occur in diabetic
nephropathy, it is sometimes difficult to precisely identify
the cells that undergo MFT and EMT. Apparently, many
derive from intrinsic mesangial cells, tubular epithelial cells,
and perhaps pericytes. However, recent experiments suggest
another possibility and are leading investigators to wonder if
cells undergoing MFT and EMT might arise from bone
marrow-derived progenitors (Figure 2).
Bone marrow-derived progenitors in nonrenal models of
organ fibrosis
To define the role of progenitor cells in MFT and EMT,
irradiated mice are given bone marrow grafts from sex-
mismatched controls or from mice expressing marker genes
such as luciferase or green fluorescent protein. The extent to
which donor cell engraftment contributes to MFT and EMT
is analyzed by measuring the proportion of cells positive for
the Y chromosome, using antibodies against luciferase or
assessing fluorescence. Using these techniques in conjunction
with markers of MFT or EMT, bone marrow-derived
progenitor cells were identified as a source of myofibroblasts
in peripheral tissues.
Typically, in response to injury, bone marrow-derived
myofibroblasts have been shown to expand and contribute to
fibrosis in the lung,57,58 liver,59 skin,58 and peritoneum.60 In a
murine model of cirrhosis, B70% of liver myofibroblasts
derived from bone marrow and most of these myofibroblasts
actively secreted collagen type I.59
In another study of patients with liver fibrosis of diverse
etiologies, a significant proportion of myofibroblasts was
shown to derive from bone marrow progenitors.61 These
patients had bone marrow transplants from opposite sex
donors, so the derivation of myofibroblasts was classified by
the presence of a Y chromosome in cells that were positive for
myofibroblast markers. Although it is possible to use this
approach to identify cells derived from bone marrow
progenitors, it is difficult to assign an origin to the remainder
of myofibroblasts that did not come from bone marrow
progenitors.
Although the studies cited above suggest that myofibro-
blasts can derive from bone marrow progenitors, their
contribution to fibrosis is debated. For instance, in a mouse
model of bleomycin-induced lung fibrosis, bone marrow cells
contribute little to the accumulation of fibroblasts and most
of the collagen type I-producing cells are not from bone
marrow.62 In a model of cardiac fibrosis, bone marrow-
derived progenitors do not produce myofibroblasts.63 Using a
sensitive green fluorescent protein under transcriptional
control of the aSMA promoter, another study in mice has
failed to detect significant numbers of aSMA-positive
myofibroblasts that derive from bone marrow.64 It is difficult
to reconcile these disparate findings, but the results support
the contention that fibroblasts are phenotypically hetero-
geneous and that the response of these fibroblasts depends on
injury- and tissue-specific cues.65
Bone marrow-derived progenitors and renal fibrosis
In the kidney, the ability of bone marrow progenitors to
produce effector cells appears to depend upon both nephron
localization and the specific injury producing fibrosis.
Previous studies have shown that cells from the metanephric
mesenchyme and the bone marrow can transdifferentiate into
renal myofibroblasts.66 In mice, a population of mesangial
cells arise from bone marrow, possibly from hematopoietic
stems cells of a granulocyte/macrophage origin.64,67–71 These
bone marrow-derived mesangial progenitors can repopulate
glomeruli after kidney injury68,71,72 and a glomerulosclerosis
phenotype can be conferred by bone marrow transplanta-
tion.67 A role for bone marrow progenitors in tubulointer-
stitial remodeling remains uncertain.72 In a model of renal
fibrosis induced by ureteral obstruction and characterized by
tubulointerstitial fibrosis, bone marrow progenitors produce
a population of interstitial myofibroblasts,26,73 but collagen
type I transcription in these cells is not observed.73 The
possibility that collagen I synthesis is upregulated by post-
transcriptional mechanisms was not investigated. In obstruc-
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tion, the Col1a2 promoter is most active in tubular cells,47,73
suggesting that tubular epithelium, not bone marrow-derived
progenitors, secrete collagen I. Similarly, in a renal model of
endothelial injury, bone marrow progenitors do not con-
tribute significantly to interstitial fibrosis.74 Collectively, these
results suggest that bone marrow-derived progenitors give
rise to matrix-producing mesangial cells, but the contribu-
tion to tubulointerstitial fibrosis is less certain and might
depend on the type of injury.
Diabetic nephropathy and bone marrow-derived progenitors
The contribution of bone marrow-derived progenitors to
MFT and EMT in diabetes or more specifically in diabetic
nephropathy is a question that researchers are investigating.
A recent study reported that the number of bone marrow-
derived myofibroblast progenitors is 1.6-fold higher in
patients with type 1 diabetes compared with nondiabetic
controls,75 suggesting that diabetes might induce a profi-
brotic state. The mechanism by which type 1 diabetes
increases the number of bone marrow progenitor cells is
uncertain but might be related to a relative deficiency in bone
morphogenetic protein (BMP) 6, which inhibits transcrip-
tion of genes that initiate the MFT response.75
In db/db mice, a genetic model of type 2 diabetes in which
the mice lack the leptin receptor, bone marrow-derived
progenitors can transfer the diabetic glomerular phenotype
(i.e., mesangial expansion and glomerulosclerosis) to non-
diabetic normoglycemic mice.76 Studies in experimental
models of diabetes seem warranted to define the role of
progenitor cells in MFT, EMT, and renal fibrosis in diabetes
(Figure 2). These studies seem especially relevant given that
some have proposed the use of stem or progenitor cells to
treat glomerular fibrosis in vivo.77
MFT, EMT, AND THE PATHOGENESIS OF FIBROSIS IN
DIABETIC NEPHROPATHY
Two lines of evidence suggest that MFT and EMT
functionally contribute to fibrosis in diabetic nephropathy:
1. The same extracellular cues that induce MFT and EMT
also increase fibrosis.
2. Inhibitors of MFT and EMT attenuate or block fibrosis
and progressive kidney disease in animal models of
diabetes (Figure 3).
Molecular mediators of MFT and EMT in diabetic
nephropathy
The cytokine TGFb, a critical profibrotic mediator,2,4,16,18 is
elevated in diabetes and strongly induces MFT and EMT
(Figure 3). TGFb induces aSMA and collagen type I in
human mesangial cells78 and also increases mesangial cell
hypertrophy in vitro and in vivo. In tubular epithelial cells,
TGFb induces aSMA and represses E-cadherin,79 demon-
strating that TGFb is a potent stimulus for EMT. The
importance of TGFb has also been demonstrated in mice
overexpressing TGFb in the kidney. Transgenic expression of
TGFb in the kidney causes robust fibrosis in the glomerulus
and tubulointerstitium.
High glucose is another potential stimulus of MFT and
EMT, but surprisingly, the extent to which hyperglycemia
directly stimulates phenotypic transitions in kidney cells is
unclear. Hyperglycemia induces synthesis of numerous
matrix proteins by mesangial cells including collagen I, III,
IV fibronectin, and laminin (reviewed by Mason and Abdel
Wahab2). High extracellular glucose also promotes collagen
accumulation in proximal tubule epithelial cells80,81 and
elevates AGEs. In vivo, these AGEs promote crosslinking of
extracellular matrix proteins and slow degradation by
endogenous proteases.82,83 In vitro, AGEs stimulate EMT,
which is attenuated by a crosslink breaker that neutralizes the
effect of AGEs, suggesting a causative role.42,52 Similarly, in
cultured tubule cells, the receptor for AGEs induces EMT by a
TGFb-dependent pathway,52 suggesting that AGEs may
require TGFb. Induction of EMT by AGEs also requires
connective tissue growth factor.84 Obviously, hyperglycemia
is a huge factor in diabetes, but high glucose per se has not
been established as a stimulus of the full complement of
TGF, ANG II
ET-1, shear stress
TGF, ANG II
ET-1, FGF-2, AGEs
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Figure 3 | Working model for regulation of MFT and EMT in the
diabetic kidney. Induction of MFT and EMT requires a shift in the
balance between positive and negative regulators. Numerous
paracrine or autocrine factors stimulate MFT and EMT including TGFb,
endothelin-1 (ET-1), angiotensin II (ANG II), and perhaps high glucose
(HG), fibroblast growth factor 2 (FGF2), AGEs, and BMDC, bone
marrow-derived cells. Repression of MFT and EMT involves HGF, BMP-
7, angiotensin-converting enzyme inhibitors (ACEI), and retinoic acid
(RA).
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metaplastic phenotypes (i.e., aSMA induction and E-
cadherin repression).
A third factor that might induce MFT and EMT in the
kidney is mechanical stress (Figure 3). Hemodynamic forces
(i.e., transmural pressure and shear stress) cause mechanical
stress that promotes glomerular injury early in the natural
history of diabetes. However, whether or not hemodynamic
stress leads to MFT in the diabetic kidney is unknown. What
is known is that sheer stress and other mechanical forces
promote MFT in vitro,46,85 providing a rationale for future
study. Mechanically stimulated MFT in mesangial cells might
explain, in part, why systemic hypertension and glomerular
hyperfiltration amplify kidney injury in diabetes. Indeed,
mechanotransduction is an attractive candidate for linking
hemodynamic stress to MFT of kidney cells.
Anti-metaplastic regulators block fibrosis in diabetic
nephropathy
A second reason to implicate MFT and EMT in diabetic
nephropathy is that negative regulators block renal fibrosis in
diabetes. For example, hepatocyte growth factor (HGF, also
known as scatter factor) is a potent anti-fibrotic hormone
that blocks both MFT (in mesangial cells and interstitial
fibroblasts) and EMT (of tubular epithelial cells) in vitro and
in vivo.50,86–88 That HGF inhibits EMT makes sense because
HGF directs tubulogenesis in embryonic development by the
opposite mechanism that initiates EMT: the mesenchyma-
l–epithelial transition. In mice treated with STZ, renal
delivery of an exogenous HGF gene reduced mesangial
expansion, glomerular fibronectin, and collagen type I.50,88
HGF also:
K Reverses glomerulosclerosis in diabetic rats.87
K Reduces albuminuria and renal fibrosis. Inhibits
MFT of interstitial fibroblasts in the diabetic mouse
and rat kidney, thereby attenuating tubulointersti-
tial fibrosis.50,87
K Lowers renal tissue and urinary TGFb, which might
be a mechanism by which HGF blocks fibrosis in
STZ diabetic rodent kidneys.
K Blocks fibrosis and improves renal function in db/db
mice,89 although a direct effect on the phenotypic
transitions has not been tested extensively.
Additionally, HGF mediates the anti-fibrotic action of
peroxisome proliferator-activated receptor-g, a nuclear hor-
mone receptor that regulates transcription. Natural and
synthetic peroxisome proliferator-activated receptor-g ago-
nists increase HGF, which in turn blocks aSMA and matrix
accumulation in mesangial cells and renal interstitial
fibroblasts exposed to TGFb.90 Peroxisome proliferator-
activated receptor-g also activates transcription from the
HGF promoter.
HGF mediates the anti-fibrotic action of another nuclear
hormone receptor, the retinoic acid-receptor superfamily.
Mesangial cells exposed to retinoic acid fail to develop into
myofibroblasts when exposed to TGFb.91 Another ligand that
binds to nuclear hormone receptors 1,25-dihydroxyvitamin
D also represses renal fibrosis by an HGF-based mechan-
ism.92 This anti-fibrotic effect of HGF is also consistent with
a role for MFT and EMT in the pathogenesis of renal fibrosis
in diabetes. These results highlight the anti-fibrotic potential
of retinoic acid, 1,25-dihydroxyvitamin D and peroxisome
proliferator-activated receptor-g agonists such as the thiazo-
lidinediones and provide solid rationale for pursuing a
therapeutic application for HGF.
However, the potential therapeutic role of HGF has been
questioned in studies showing that chronically elevated HGF
contributes to a decline in growth factor receptor, increases
microalbuminuria, and promotes progression of diabetic
nephropathy in db/db mice.93 In addition, mice overexpres-
sing HGF developed tubular hyperplasia, glomerulosclerosis,
and a phenotype resembling polycystic kidney disease.94 It is
possible that these discrepant effects of HGF are explained by
differences in the genetic background of model systems, so
further studies on new models are necessary to determine the
therapeutic potential of HGF in diabetic nephropathy.
Moreover, HGF and its receptor c-Met promote cancer cell
migration and expression of angiogenic factors,95 so the
proto-oncogenic action of HGF and c-Met might limit
clinical utility.
Renal fibrosis in diabetes is also inhibited by BMP-7,
another ligand that blocks EMT in vitro and in vivo.28 In
published studies, BMP-7 slowed progression of nephropathy
in STZ rats96 and db/db mice97 and preserved glomerular
filtration rate, glomerular size, and permeability better than
or equal to Enalapril. Interestingly, the effects of BMP-7
occur without lowering blood pressure.96 BMP-7 also inhibits
collagen accumulation, making it a potent anti-fibrotic agent
in this model. The extent to which the anti-fibrotic effect of
BMP-7 reflects its ability to block EMT has not been directly
tested. Like HGF, BMP-7 inhibits signals evoked by the TGFb
receptor in mesangial cells.98,99 The in vivo relevance of BMP-
7’s antifibrotic action is supported by experiments in mice
transgenic for noggin, an endogenous inhibitor of BMPs.
Transgenic noggin mice develop massive expansion of the
mesangial matrix and accumulation of fibronectin.100
Another link between BMPs and fibrosis in diabetic
nephropathy is gremlin, the endogenous inhibitor of BMPs.
Gremlin limits BMP availability, thereby reducing the
threshold for induction of MFT and EMT by TGFb, and it
is markedly elevated in humans with diabetic nephropathy.
Hyperglycemia and TGFb induce the gremlin gene in
mesangial cells101 and the spatiotemporal pattern of gremlin
expression is consistent with a role in tubulointerstitial
fibrosis.102
CONCLUSIONS AND FUTURE DIRECTIONS
Our assumptions about the role of MFT and EMT derive
primarily from experimental models of renal disease in
rodents. Given the potential differences between humans and
rodents, results derived in rats and mice must be interpreted
with caution. It is unclear to what extent these results can be
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extrapolated to humans with diabetic nephropathy. However,
the role of MFT and EMT in human development is quite
similar to that in rodents, supporting the notion that these
phenotypic transitions are relevant to renal fibrosis in humans.
A model of fibrosis in diabetic nephropathy that
encompasses MFT and EMT provides a conceptual frame-
work for interpreting new findings and developing ther-
apeutic approaches. For instance, an effective therapeutic
approach will probably need to block the multiple pheno-
typic transitions that occur in diabetic nephropathy. In
addition, a considerable body of work has delineated the
regulation of MFT and EMT in development, which should
yield productive clues for anti-fibrotic therapies.
Finally, there is understandable enthusiasm regarding
remission or regression of renal fibrosis. Therefore, it will
be important to determine whether these altered cells can
revert to their normal phenotype or whether the cells must
die out or be replaced. In development, EMT is reversible,
but in fibrosis it is not clear whether reprogramming of the
target cell is permanent.
Below are some pressing questions for research in this
area:
1. What is the origin of fibrosis effector cells in diabetic
nephropathy? Do they derive from progenitors, circulat-
ing fibrocytes, or only from intrinsic renal cells? It will be
especially important to determine the contribution, if
any, of hematopoietic stem cells to the emergence of
myofibroblasts and fibroblastic cells in the diabetic
kidney. If progenitors contribute to fibrosis, the pheno-
type of any progenitors used for renal replacement
therapy would have to be tightly regulated.
2. Do infiltrating inflammatory cells induce MFT or EMT of
normal kidney cells? Although some studies have
demonstrated macrophages in the diabetic kidney, scant
attention has been focused on the contribution of
lymphocytes to induction of MFT, EMT, and the
progression of fibrosis. Macrophages have been shown
to induce fibrosis in the liver and a similar effect might
be operative in the diabetic kidney.
3. What technical advances are necessary to study the
functional role of MFT and EMT in renal fibrosis in
diabetes? Noninvasive markers of renal fibrosis are
urgently needed for animal model studies and for
determining the natural history of fibrosis in patients
with diabetic nephropathy. Currently, measurements of
renal fibrosis in patients require renal biopsy, precluding
large population-based studies. The development of anti-
fibrotic strategies will rely on noninvasive markers for
surrogate end points. Possible markers include serum
and urine proteins (e.g., cytokines, collagen peptide
fragments) and imaging. For example, TGFb and
connective tissue growth factor in urine tightly associates
with albuminuria and renal injury in patients with type 1
and 2 diabetes.103,104
4. Finally, what are the cellular and molecular mechanisms
that initiate and inhibit MFT and EMT in diabetic
nephropathy? Although much is known about the
regulation of MFT and EMT in nondiabetic kidney
disease, the extent to which similar mechanisms operate
in diabetic nephropathy is not completely understood.
New therapeutic approaches might evolve from a better
understanding of the mechanisms that control these
profibrotic phenotypic transitions in diabetes.
ACKNOWLEDGMENTS
This work has been supported by grants from the Rosenberg
Foundation of the Centers for Dialysis Care (Cleveland, Ohio, USA)
and the NIH. We thank Fuad Ziyadeh MD for critically reviewing the
paper and Pamela Hunt-Cloyd for expert editorial assistance.
REFERENCES
1. Ziyadeh FN, Sharma K. Combating diabetic nephropathy. J Am Soc
Nephrol 2003; 14: 1355–1357.
2. Mason RM, Abdel Wahab N. Extracellular matrix metabolism in diabetic
nephropathy. J Am Soc Nephrol 2003; 14: 1358–1373.
3. Caramori ML, Mauer M. Diabetes and nephropathy. Curr Opin Neprol
Hypertens 2003; 12: 273–282.
4. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular
capillary wall toward the center of disease. Diabetes 2005; 54:
1626–1634.
5. Fogo AB, Kashgarian M. Vascular diseases- Diabetic nephropathy. In:
Fogo AB, Kashgarian M (eds). Diagnostic Atlas Renal Pathology.
Philadelphia: Elsevier, 2005 pp 277–289.
6. Eddy AA. Can renal fibrosis be reversed? Pediatr Nephrol 2005; 20:
1369–1375.
7. Fogo AB. The potential for regression of renal scarring. Curr Opin
Nephrol Hypertens 2003; 12: 223–225.
8. Harris RC, Neilson EG. Toward a unified theory of renal progression.
Annu Rev Med 2006; 57: 365–380.
9. Chatziantoniou C, Dussaule JC. Insights into the mechanisms of renal
fibrosis: is it possible to achieve regression? Am J Physiol Renal Physiol
2005; 289: F227–F234.
10. Fioretto P, Steffes MW, Sutherland D et al. Reversal of lesions of diabetic
nephropathy after pancreas transplantation. New Engl J Med 1998; 339:
69–75.
11. Fioretto P, Sutherland DE, Najafian B et al. Remodeling of renal
interstitial and tubular lesions in pancreas transplant recipients. Kidney
Int 2006; 69: 907–912.
12. Nath KA. Tubulointerstitial changes as a major determinant in the
progression of renal damage. Am J Kidney Dis 1992; 20: 1–17.
13. Healy E, Brady HR. Role of tubular epithelial cells in the pathogenesis of
tubulointerstitial fibrosis induced by glomerular disease. Curr Opin
Nephrol Hypertens 1998; 7: 525–530.
14. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic
kidney disease: more than an aftermath of glomerular injury? Kidney Int
1999; 56: 1627–1637.
15. Katz A, Caramori ML, Sisson-Ross S et al. An increase in the cell
component of the cortical interstitium antedates interstitial fibrosis in
type 1 diabetic patients. Kidney Int 2002; 61: 2058–2066.
16. Border WA, Noble NA. Transforming growth factor b in tissue fibrosis.
New Engl J Med 1994; 331: 1286–1292.
17. Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal
insufficiency, excess matrix gene expression, and glomerular mesangial
matrix expansion by treatment with monoclonal anti-transforming
growth factorb antibody in db/db diabetic mice. Proc Natl Acad Sci USA
2000; 97: 7667–7669.
18. Schnaper HW, Hayashida T, Hubchak SC et al. TGF-b signal transduction
and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284:
F243–F252.
19. Liu Y. Renal fibrosis: new insights into the pathogenesis and
therapeutics. Kidney Int 2006; 69: 213–217.
20. Kalluri R, Neilson EG. Epithelial–mesenchymal transition and its
implications for fibrosis. J Clin Invest 2003; 112: 1776–1784.
21. Neilson EG. Mechanisms of disease: fibroblasts – a new look at an old
problem. Nat Clin Pract Nephrol 2006; 2: 101–108.
22. Powell DW, Mifflin RC, Valentich JD et al. Myofibroblasts. I. Paracrine cells
important in health and disease. Am J Physiol 1999; 277: C1–C9.
852 Kidney International (2007) 71, 846–854
r e v i e w MS Simonson: Fibrosis in diabetic nephropathy
23. Schelling JR, Sinha S, Konieczkowski M et al. Myofibroblast
differentiation: plasma membrane microdomains and cell phenotype.
Exp Nephrol 2002; 10: 313–319.
24. Desmouliere A, Darby IA, Gabbiani G. Normal and pathologic soft tissue
remodeling: role of the myofibroblast, with special emphasis on liver
and kidney fibrosis. Lab Invest 2003; 83: 1689–1707.
25. Leask A, Abraham DJ. TGF-b signaling and the fibrotic response. FASEB J
2004; 18: 816–827.
26. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from
epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341–350.
27. Liu Y. Epithelial to mesenchymal transition in renal fibrosis: pathologic
significance, molecular mechanism, and therapeutic intervention. J Am
Soc Nephrol 2004; 15: 1–12.
28. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts
TGF-b1-induced epithelial-to-mesenchymal transition and reverses
chronic renal injury. Nat Med 2003; 9: 964–968.
29. Bou-Gharios G, Ponticos M, Rajkumar V et al. Extra-cellular matrix in
vascular networks. Cell Prolif 2004; 37: 207–220.
30. Raghow R. The role of extracellular matrix in postinflammatory wound
healing and fibrosis. FASEB J 1994; 8: 823–831.
31. Tosh D, Slack JM. How cells change their phenotype. Nat Rev Mol Cell
Biol 2002; 3: 187–194.
32. Hay ED. The mesenchymal cells, its role in the embryo, and the
remarkable signaling mechanisms that create it. Dev Dynam 2005; 233:
706–720.
33. Li WC, Yu WY, Quinlan JM et al. The molecular basis of
transdifferentiation. J Cell Mol Med 2005; 9: 569–582.
34. Pomerantz J, Blau HM. Nuclear reprogramming: a key to stem cell
function in regenerative medicine. Nat Cell Biology 2004; 6: 810–816.
35. Collas P, Hakelien AM. Teaching cells new tricks. Trends Biotechnol 2003;
21: 354–361.
36. Latta H. An approach to the structure and function of the glomerular
mesangium. J Am Soc Nephrol 1992; 2: S65–S73.
37. Mene P, Simonson MS, Dunn MJ. Physiology of the mesangial cell.
Physiol Rev 1989; 69: 1347–1424.
38. Johnson RJ, Floege J, Yoshimura A et al. The activated mesangial cell: a
glomerular ‘myofibroblast’? J Am Soc Nephrol 1992; 2(S2): S190–S197.
39. Alexakis C, Maxwell P, Bou-Gharios G. Organ-specific collagen
expression: implications for renal disease. Nephron Exp Nephrol 2006;
102: e71–e75.
40. Dalla Vestra M, Saller A, Mauer M et al. Role of mesangial expansion in
the pathogenesis of diabetic nephropathy. J Nephrol 2001; 14:
S51–S57.
41. Fogo AB. Mesangial matrix modulation and glomerulosclerosis. Exp
Nephrol 1999; 7: 147–159.
42. Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating
tubular epithelial to mesenchymal transition and renal interstitial
fibrogenesis. J Clin Invest 2003; 112: 503–516.
43. Strutz F, Okada H, Lo CW et al. Identification and characterization of a
fibroblast marker: FSP1. J Cell Biol 1995; 130: 393–405.
44. Ng YY, Huang TP, Yang WC et al. Tubular epithelial-myofibroblast
transdifferentiation in progressive tubulointerstitial fibrosis in 5/6
nephrectomized rats. Kidney Int 1998; 54: 864–876.
45. Thiery JP, Sleeman JP. Complex networks orchestrate
epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7:
131–142.
46. Tomasek JJ, Gabbiani G, Hinz B et al. Myofibroblasts and
mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell
Biol 2002; 3: 349–363.
47. Ponticos M, Abraham D, Alexakis C et al. Col1a2 enhancer regulates
collagen activity during development and in adult tissue repair. Matrix
Biol 2004; 22: 619–628.
48. Ina K, Kitamura H, Tatsukawa S et al. Transformation of interstitial
fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy. Med
Electron Microsc 2002; 35: 87–95.
49. Coimbra TM, Janssen U, Grone HJ et al. Early events leading to renal
injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000;
57: 167–182.
50. Dai C, Yang J, Bastacky S et al. Intravenous administration of hepatocyte
growth factor gene ameliorates diabetic nephropathy in mice. J Am Soc
Nephrol 2004; 15: 2637–2647.
51. Matsubara T, Abe H, Arai H et al. Expression of Smad1 is directly
associated with mesangial matrix expansion in rat diabetic
nephropathy. Lab Invest 2006; 86: 357–368.
52. Oldfield MD, Bach LA, Forbes JM et al. Advanced glycation end products
cause epithelial-myofibroblast transdifferentiation via the receptor for
advanced glycation end products (RAGE). J Clin Invest 2001; 108:
1853–1863.
53. Essawy M, Soylemezoglu O, Muchaneta-Kubara EC et al. Myofibroblasts
and the progression of diabetic nephropathy. Nephrol Dial Transplant
1997; 12: 43–50.
54. Pedagogos E, Hewitson T, Fraser I et al. Myofibroblasts and arteriolar
sclerosis in human diabetic nephropathy. Am J Kidney Dis 1997; 29:
912–918.
55. Rastaldi MP, Ferrario F, Giardino L et al. Epithelial–mesenchymal
transition of tubular epithelial cells in human renal biopsies. Kidney Int
2002; 62: 137–146.
56. Makino H, Kashihara N, Sugiyama H et al. Phenotypic modulation of the
mesangium reflected by contractile proteins in diabetes. Diabetes 1996;
45: 488–495.
57. Direkze NC, Forbes SJ, Brittan M et al. Multiple organ engraftment
by bone-marrow-derived myofibroblasts and fibroblasts in
bone-marrow-transplanted mice. Stem Cells 2003; 21: 514–520.
58. Ishii G, Sangai T, Sugiyama K et al. In vivo characterization of bone
marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells
2005; 23: 699–706.
59. Russo FP, Alison MR, Bigger BW et al. The bone marrow
functionally contributes to liver fibrosis. Gastroenterology 2006;
130: 1807–1821.
60. Jabs A, Moncada GA, Nichols CE et al. Peripheral blood mononuclear
cells acquire myofibroblast characteristics in granulation tissue. J Vasc
Res 2005; 42: 174–180.
61. Forbes SJ, Russo FP, Rey V et al. A significant proportion of
myofibroblasts are of bone marrow origin in human liver fibrosis.
Gastroenterology 2004; 126: 955–963.
62. Hashimoto N, Jin H, Liu T et al. Bone marrow-derived progenitor cells in
pulmonary fibrosis. J Clin Invest 2004; 113: 243–252.
63. Yano T, Miura T, Ikeda Y et al. Intracardiac fibroblasts, but not bone
marrow derived cells, are the origin of myofibroblasts in myocardial
infarct repair. Cardiovasc Pathol 2005; 14: 241–246.
64. Yokota T, Kawakami Y, Nagai Y et al. Bone marrow lacks a transplantable
progenitor for smooth muscle type alpha-actin-expressing cells. Stem
Cells 2006; 24: 13–22.
65. Chang HY, Chi JT, Dudoit S et al. Diversity, topographic differentiation,
and positional memory in human fibroblasts. Proc Natl Acad Sci USA
2002; 99: 12877–12882.
66. Oliver JA, Barasch J, Yang J et al. Metanephric mesenchyme contains
embryonic renal stem cells. Am J Physiol Renal Physiol 2002; 283: F799–809.
67. Cornacchia F, Fornoni A, Plati AR et al. Glomerulosclerosis is transmitted
by bone marrow-derived mesangial cell progenitors. J Clin Invest 2001;
108: 1649–1656.
68. Imasawa T, Utsunomiya Y, Kawamura T et al. The potential of bone
marrow-derived cells to differentiate to glomerular mesangial cells. J Am
Soc Nephrol 2001; 12: 1401–1409.
69. Abe T, Fleming PA, Masuya M et al. Granulocyte/macrophage origin of
glomerular mesangial cells. Int J Hematol 2005; 82: 115–118.
70. Brodie JC, Humes HD. Stem cell approaches for the treatment of renal
failure. Pharmacol Rev 2005; 57: 299–313.
71. Vigneau C, Zheng F, Polgar K et al. Stem cells and kidney injury. Curr
Opin Nephrol Hypertens 2006; 15: 238–244.
72. Szczypka MS, Westover AJ, Clouthier SG et al. Rare incorporation of
bone marrow-derived cells into kidney after folic acid-induced injury.
Stem Cells 2005; 23: 44–54.
73. Roufosse C, Bou-Gharios G, Prodromidi E et al. Bone marrow-derived
cells do not contribute significantly to collagen I synthesis in a murine
model of renal fibrosis. J Am Soc Nephrol 2006; 17: 775–782.
74. Faulkner JL, Szcykalski LM, Springer F et al. Origin of interstitial
fibroblasts in an accelerated model of angiotensin II-induced renal
fibrosis. Am J Pathol 2005; 167: 1193–1205.
75. Nguyen TQ, Chon H, van Nieuwenhoven FA et al. Myofibroblast
progenitor cells are increased in number in patients with type 1
diabetes and express less bone morphogenetic protein 6: a novel clue
to adverse tissue remodelling? Diabetologia 2006; 49: 1039–1048.
76. Zheng F, Cornacchia F, Schulman I et al. Development of albuminuria and
glomerular lesions in normoglycemic B6 recipients of db/db mice bone
marrow: the role of mesangial cell progenitors. Diabetes 2004; 53: 2420–2427.
77. Li B, Morioka T, Uchiyama M et al. Bone marrow cell infusion
amerliorates progressive glomerulosclerosis in an experimental rat
model. Kidney Int 2006; 69: 323–330.
78. Dai C, Liu Y. Hepatocyte growth factor antagonizes the profibrotic
action of TGFb1 in mesangial cells by stabilizing Smad transcriptional
corepressor TGIF. J Am Soc Nephrol 2004; 15: 1402–1412.
Kidney International (2007) 71, 846–854 853
MS Simonson: Fibrosis in diabetic nephropathy r e v i e w
79. Yang J, Liu Y. Dissection of key events in tubular epithelial to
myofibroblast transition and its implications in renal interstitial fibrosis.
Am J Pathol 2001; 159: 1465–1475.
80. Skill NJ, Johnson TS, Coutts IG et al. Inhibition of transglutaminase
activity reduces extracellular matrix accumulation induced by high
glucose levels in proximal tubular epithelial cells. J Biol Chem 2004; 279:
47754–47762.
81. Kobayashi T, Inoue T, Okada H et al. Connective tissue growth factor
mediates the profibrotic effects of transforming growth factor b
produced by tubular epithelial cells in response to high glucose. Clin Exp
Nephrol 2005; 9: 114–121.
82. Brownlee M. The pathobiology of diabetic complications. Diabetes 2005;
54: 1615–1625.
83. Cooper ME. Importance of advanced glycation end products in
diabetes-associated cardiovascular and renal disease. Am J Hypertens
2004; 17: 31S–38S.
84. Burns WC, Twigg SM, Forbes JM et al. Connective tissue growth factor
plays an important role in advanced glycation end product-induced
tubular epithelial-to-mesenchymal transition: implications for diabetic
renal disease. J Am Soc Nephrol 2006; 17: 2484–2494.
85. Ng CP, Hinz B, Swartz MA. Interstitial fluid flow induces myofibroblast
differentiation and collagen alignment in vitro. J Cell Sci 2005; 118:
4731–4739.
86. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis: the role
of bone morphogenic protein-7 and hepatocyte growth factor. Kidney
Int 2003; 64(Suppl 87): S105–S112.
87. Cruzado JM, Lloberas N, Torras J et al. Regression of advanced diabetic
nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes
2004; 53: 1119–1127.
88. Mizuno S, Nakamura T. Suppressions of chronic glomerular injuries and
TGFb1 production by HGF in attenuation of murine diabetic
nephropathy. Am J Physiol 2004; 286: F134–F143.
89. Kagawa T, Takemura G, Kosai K et al. Hepatocyte growth factor gene
therapy slows down the progression of diabetic nephropathy in db/db
mice. Nephron Physiol 2006; 102: 92–102.
90. Li Y, Wen X, Spataro BC et al. Hepatocyte growth factor is a downstream
effector that mediates the antifibrotic action of peroxisome
proliferators-activated receptor-g agonists. J Am Soc Nephrol 2006; 17:
54–65.
91. Wen X, Li Y, Hu K et al. Hepatocyte growth factor receptor signaling
mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular
mesangial cells. Am J Pathol 2005; 167: 947–957.
92. Li Y, Spataro BC, Yang J et al. 1,25-dihydroxyvitamin D inhibits renal
interstitial myofibroblast activation by inducing hepatocyte growth
factor expression. Kidney Int 2005; 68: 1500–1510.
93. Laping NJ, Olson BA, Ho T et al. Hepatocyte growth factor: a regulator of
extracellular matrix genes in mouse mesangial cells. Biochem Pharmacol
2000; 59: 847–853.
94. Takayama H, LaRochelle WJ, Sabnis SG et al. Renal tubular hyperplasia,
polycystic disease, and glomerulosclerosis in transgenic mice
overexpressing hepatocyte growth factor/scatter factor. Lab Invest 1997;
77: 131–138.
95. Ren Y, Cao B, Law S et al. Hepatocyte growth factor promotes cancer cell
migration and angiogenic factors expression: A prognostic marker of
human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11:
6190–6197.
96. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a
novel therapy for diabetic nephropathy. Kidney Int 2003; 63: 2037–2049.
97. Wang S, de Caestecker M, Kopp J et al. Renal bone morphogenetic
protein-7 protects against diabetic nephropathy. J Am Soc Nephrol 2006;
17: 2504–2512.
98. Wang S, Hirschberg R. BMP7 antagonizes TGF-b-dependent fibrogenesis
in mesangial cells. Am J Physiol Renal Physiol 2003; 284: F1006–F1013.
99. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing
transforming growth factor b in mesangial cells. J Biol Chem 2004; 279:
23200–23206.
100. Miyazaki Y, Ueda H, Yokoo T et al. Inhibition of endogenous BMP in the
glomerulus leads to mesangial matrix expansion. Biochem Biophys Res
Commun 2006; 340: 681–688.
101. McMahon R, Murphy M, Clarkson M et al. IHG-2, a mesangial cell gene
induced by high glucose, is human gremlin. Regulation by extracellular
glucose concentration, cyclic mechanical strain, and transforming
growth factor-beta 1. J Biol Chem 2000; 275: 9901–9904.
102. Dolan V, Murphy M, Sadlier D et al. Expression of gremlin, a bone
morphogenetic protein antagonist, in human diabetic nephropathy. Am
J Kidney Dis 2005; 45: 1034–1039.
103. Houlihan CA, Akdeniz A, Tsalamandris C et al. Urinary transforming
growth factor-b excretion in patients with hypertension, type 2
diabetes, and elevated albumin excretion rate: effects of angiotensin
receptor blockade and sodium restriction. Diabetes Care 2002; 25:
1072–1077.
104. Gilbert RE, Akdeniz A, Weitz S et al. Urinary connective tissue growth
factor excretion in patients with type 1 diabetes and nephropathy.
Diabetes Care 2003; 26: 2632–2636.
854 Kidney International (2007) 71, 846–854
r e v i e w MS Simonson: Fibrosis in diabetic nephropathy
